Christian Kellner
0000-0002-2562-6902
68 papers found
Refreshing results…
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells
A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries
AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma.
Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity
The novel chimeric CDw75 antibody chEBU-141 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) against mature B-lineage neoplasms
CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells
An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity
Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients
Anti-myeloma activity of the novel ADCC-optimized human CD54 (ICAM-1) antibody MSH-TP15e.
CD96 Antibody TH-111 Eradicates AML-LSC from Autografts and the Fc- Engineered Variant MSH-TH111e May be Used In Vivo
EGFR antibodies in immunotherapy: complement optimized antibody enhances polymorphonuclear cell mediated killing
Dual Fc-optimization of therapeutic antibodies for improved lymphoma therapy enhanced complement-dependent and cell-mediated cytotoxicity by combined glyco- and protein-engineering
An Fc-engineered CD19 antibody engages NK cells and macrophages and is effective in Xenograft models of acute lymphoblastic leukemia
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells
Missing publications? Search for publications with a matching author name.